First-Line Treatment and Survival in Women Aged ≥ 70 Years with De Novo Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Cohort Study by the Turkish Oncology Group
JOURNAL OF CLINICAL MEDICINE, cilt.15, sa.22, ss.1-22, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 15 Sayı: 22
- Basım Tarihi: 2026
- Doi Numarası: 10.3390/jcm15228979
- Dergi Adı: JOURNAL OF CLINICAL MEDICINE
- Derginin Tarandığı İndeksler: Scopus, Science Citation Index Expanded (SCI-EXPANDED), PubMed
- Sayfa Sayıları: ss.1-22
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Recep Tayyip Erdoğan Üniversitesi Adresli: Evet
Özet
Background: Real-world evidence regarding first-line treatment selection and clinical outcomes in women aged 70 years and older with de novo hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer remains limited. This study evaluated treatment patterns, survival outcomes, and treatment-related adverse events in this population. Methods: This multicenter retrospective study included 181 women aged ≥ 70 years with de novo HR+/HER2− metastatic breast cancer treated at 14 oncology centers in Türkiye between January 2016 and January 2026. Patients receiving first-line cyclin-dependent kinase 4/6 inhibitors plus aromatase inhibitors (CDK4/6i + AI; n = 136) were compared with those receiving other first-line regimens (n = 45). Treatment selection was evaluated using logistic regression, while progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates and Cox regression. Results: CDK4/6i + AI was administered to 75.1% of patients. ECOG performance status ≥ 2 was independently associated with lower odds of receiving combination treatment (adjusted odds ratio [aOR], 0.24; p = 0.003), whereas higher baseline left ventricular ejection fraction was associated with greater treatment receipt (aOR per 5-percentage-point increase, 1.62; p = 0.002). Median PFS was significantly longer with CDK4/6i + AI than with other treatments (43.6 vs. 12.9 months; p < 0.001), and this association persisted after adjustment, including HER2 status (adjusted hazard ratio [aHR], 0.48; 95% CI, 0.27–0.86; p = 0.013). No significant OS difference was observed (48.9 vs. 46.1 months; p = 0.205). Neutropenia was more frequent with CDK4/6i + AI (70.6% vs. 31.1%; p < 0.001). Recorded renal adverse events were also more frequent (12.5% vs. 0%; p = 0.008), although these could not be reliably distinguished from isolated creatinine elevations. Conclusions: First-line CDK4/6i + AI therapy was associated with longer PFS, without a significant OS difference, in older women with de novo HR+/HER2− metastatic breast cancer. Treatment selection was associated with functional status and cardiac function, supporting individualized therapeutic decisions beyond chronological age.